靶向人表皮生长因子受体3治疗非小细胞肺癌的研究进展

人表皮生长因子受体3（HER3/ERBB3）属于HER家族的成员，在多种癌症中广泛表达。在配体神经调节素激活下，HER3主要与表皮生长因子受体1（EGFR/ERBB1/HER1）和表皮生长因子受体2（HER2/ERBB2）形成异源二聚体，激活信号转导通路，促进肿瘤的发生和发展。研究表明，HER3不仅与非小细胞肺癌（NSCLC）的不良预后相关，且在患者耐药中起到重要作用，是NSCLC的潜在治疗靶点。目前，HER3靶向治疗药物尚未获得上市批准，但多个HER3靶向治疗药物已经进入临床试验阶段。通过对HER3与NSCLC的相关性以及目前正处于临床试验中的HER3靶向治疗NSCLC的药物进行介绍，为HER3靶向治疗药物的研发提供参考。

Advances in HER3-Targeted Therapy for Non-small Cell Lung Cancer

Human epidermal growth factor receptor 3 (HER3/ERBB3), a member of the HER family, is widely expressed in a variety of cancers. Activated by the ligand neuregulin, HER3 forms heterodimers mainly with EGFR (ERBB1/HER1) and HER2 (ERBB2) to activate signal transduction pathways and promote tumorigenesis and progression. Studies have shown that HER3 is not only associated with poor prognosis in non-small cell lung cancer (NSCLC), but also plays an important role in drug resistance in patients, making it a potential therapeutic target for NSCLC. Although no HER3-targeted therapy has been approved, several have entered clinical trials.This article describes the relevance of HER3 to NSCLC and the HER3-targeted therapy for NSCLC currently in clinical trials to provide reference for the research and development of HER3-targeted drugs.